Centes­sa gives An­toine Yver a new role, brings his old col­league on board; Pre­lude to a change: Jane Huang sets up her next move

→ Centes­sa looked to Dai­ichi Sankyo to fill the CMO post with An­toine Yver back in May 2021, and now that Yver has gar­nered a new ti­tle, why mess with a good thing?

Yver has been in­stalled as chair­man of de­vel­op­ment, and Centes­sa is go­ing back to the En­her­tu well again by ap­point­ing Javad Shahi­di as CMO. While Yver was head of on­col­o­gy R&D at Dai­ichi Sankyo, Shahi­di was the glob­al team leader for En­her­tu at the As­traZeneca part­ner. “I look for­ward to work­ing with Javad again as we con­tin­ue to grow Centes­sa with this in­cred­i­ble port­fo­lio of as­sets and come clos­er to bring­ing im­pact­ful new med­i­cines to pa­tients,” Yver said in a state­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN